JAMA Network July 11, 2025
New weight-loss drug combinations that minimize adverse effects, cardiovascular and kidney outcomes for oral semaglutide, advances in inhaled insulin for children with type 1 diabetes, and a trial of water vs diet beverages during weight management were among the hot topics at this year’s American Diabetes Association (ADA) Scientific Sessions.
JAMA Medical News recently spoke with Raveendhara Bannuru, MD, PhD, ADA’s vice president of medical affairs, about these clinical research highlights from the meeting, which took place in Chicago in June.
This interview has been edited for clarity and length.
JAMA:Several important studies were presented on glucagon peptide-1, or GLP-1, drugs. I thought we’d start with 2 phase 3 trials that tested a new dual agonist being investigated for weight...
Today's Sponsors
Today's Sponsor